La lecture à portée de main
Découvre YouScribe en t'inscrivant gratuitement
Je m'inscrisDécouvre YouScribe en t'inscrivant gratuitement
Je m'inscrisDescription
Informations
Publié par | frost-sullivan |
Publié le | 08 janvier 2014 |
Nombre de lectures | 13 |
Langue | English |
Extrait
PR Newswire
MOUNTAIN VIEW, California, Jan. 8, 2014
-- Frost & Sullivan: Ripe for innovative, non-invasive treatments, the market will almost double by 2017
The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration.